{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007710","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.723676+00:00","generated_at":"2026-05-30T03:32:07.787425+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenetic extends Scripps collaboration with $400k funding for DNase platform","bullets":["Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.","Initial $65k payment on Nov 1, 2024, followed by ~$65k monthly payments over 5 months.","Focus: systemic DNase I combined with CAR T-cell therapies for hematological cancers and melanoma.","Xenetic holds option to acquire exclusive license to new IP from the DNase research program.","Advancing DNase oncology platform toward Phase 1 for pancreatic carcinoma and solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007710","json":"https://secwatch.observer/filing/0001683168-24-007710.json","markdown":"https://secwatch.observer/filing/0001683168-24-007710.md","text":"https://secwatch.observer/filing/0001683168-24-007710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/0001683168-24-007710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:32:07.787425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}